No Data
Zhejiang Zhenyuan Share (000705.SZ) plans to sign the "Capital Increase Agreement" with CHINARES PHARMA.
On December 24th, Gelonghui reported that Zhejiang Zhenyuan Share (000705.SZ) announced that it has carried out a capital increase by introducing strategic investors for its wholly-owned subsidiary, Shaoxing Zhenyuan Pharmaceutical Operation Co., Ltd. (referred to as "Zhenyuan Pharmaceuticals"), through a public listing at the Shaoxing Property Exchange. After review by the exchange and confirmation by the company, CHINARES PHARMA was determined to be the qualified investor for the capital increase, and a "Capital Increase Agreement" is planned to be signed with CHINARES PHARMA at a price of 1.439517 yuan per registered capital, with an increase amount of 119.8618235 million yuan.
Zhejiang zhenyuan share (000705.SZ) intends to introduce a leading pharmaceutical commerce company as a new shareholder for zhenyuan pharmaceutical, raising no less than approximately 0.12 billion yuan.
Zhejiang Zhenyuan (000705.SZ) announced that the company intends to engage in a transaction with the Shaoxing Property Rights Exchange (Zhejiang Exchange...)
Zhejiang Zhenyuan: Report for the third quarter of 2024
Zhejiang Zhenyuan Share (000705.SZ): Currently, the company does not produce chinese patent medicine products.
Gelonghui, October 15th, zhejiang zhenyuan share (000705.SZ) stated on the investor interaction platform that the company's traditional chinese medicine sector mainly focuses on the production, processing, and sales of traditional chinese medicine decoction pieces. Currently, the company has not produced chinese patent medicine products.
Zhejiang Zhenyuan Seeking Public Listing for Zhenyuan Pharmaceutical Subsidiary
Zhejiang Zhenyuan (000705.SZ): Planning to introduce strategic investors through public listing for capital increase and share expansion of Zhenyuan Medicine.
Zhejiang Zhenyuan (000705.SZ) announced on September 4th that Shaoxing Zhenyuan Pharmaceutical Operation Co., Ltd. (hereinafter referred to as 'Zhenyuan Pharmaceutical') is a wholly-owned subsidiary of Zhejiang Zhenyuan Share Co., Ltd. (hereinafter referred to as 'the Company') to optimize the company's asset allocation, further meet the business development needs, enhance market competitiveness, and plan to increase capital and introduce strategic investors to Zhenyuan Pharmaceutical through public listing in property rights trading institutions. After the capital increase is completed, the proportion of shares held by strategic investors will be 51%. The audit and evaluation work of Zhenyuan Pharmaceutical is currently underway. The details of this capital increase, including the capital increase party and the amount of capital increase, are yet to be determined.
Are Zhejiang Zhenyuan Share Co.,Ltd.'s (SZSE:000705) Mixed Financials Driving The Negative Sentiment?
